Lucio Iannone

Lucio Iannone is currently Director at Axxam SpA, eGenesis, Inc., Khloris Biosciences, Inc., Immunitas Therapeutics, Inc., Kojin Therapeutics, Inc., Vesigen, Inc., Paratus Sciences Corp., and Mozart Therapeutics, Inc. He is Managing Director at A Breakthrough T1D Venture LLC starting in 2025.
He holds the positions of Vice President of Venture Investments and Vice President at Leaps By Bayer since 2021.
Former roles include Director at Azitra, Inc., GRO Biosciences, Inc., and Pyxis Oncology, Inc. from 2019 to 2021.
He was Head of Business Development at Silence Therapeutics Plc from 2015 to 2017.
Education includes a doctorate from Imperial College London, a graduate degree from the University of Cambridge conferred in 2008, and an undergraduate degree from Università degli Studi di Napoli Federico II conferred in 2006.